Background: Metastatic breast cancer remains incurable with conventional chemotherapy. For any specific chemotherapy, higher dose intensity may be achieved with either increased doses per cycle, or shortened intervals between courses, or both. We demonstrate here the feasibility and encouraging results of a high-dose combination regimen administered every two weeks.
Introduction
Breast cancer is the second highest cause of cancerrelated death in women [1] . Metastases occur in up to 50% of breast cancer patients, at which stage the disease is considered fatal. Median overall survival (OS) with conventional therapy ranges from 18 to 24 months and progression-free survival (PFS) from 6 to 12 months [2, 3] . In the mid 1980s, a large body of preclinical and clinical data supported the use of intensified and accelerated chemotherapy. Skipper et al. defined the log-kill concept which established the relationship between tumor growth kinetics and efficacy of cytotoxic agents [4] . Goldie and Coldman studied the resistance of tumoral cell lines to cytotoxic agents and hypothesized that it was related to clonal heterogeneity of the tumor, thereby explaining the potential efficacy of associations of cytostatic agents [5] . These models were based on exponential proliferation. The gompertzian model of tumoral proliferation, reinvestigated by Norton, states that the regression of a tumor is also gompertzian, and not exponential, implying that faster sublines may be eliminated before slower sublines [6] . Dose densification of chemotherapy by shortening of the interval between courses could limit regrowth time, and thereby prevent the repopulation of the tumor in the interval between two courses (reviewed in [6] ). Retrospective studies established a dose-response relationship for alkylating agents, but these results are still the subject of controversy [7, 8] . Epirubicin, a new anthracycline analog, has a better proven therapeutic index, and less cardiotoxicity, while being as active as doxorubicin [9] . Finally, the feasibility and potential efficacy of intensive and sequential chemotherapy for patients with lymphoma was reported at the time [10] .
With this as a rationale, we began an open trial in 1986 for patients with relapsing metastatic breast cancer in order to evaluate the safety profile and efficacy of accelerated chemotherapy as first-line treatment using highdose epirubicin and cyclophosphamide. This treatment was to be repeated every 14 days, whatever the neutrophil count, except in case of febrile neutropenia. No hematopoietic support was used. Initially conceived as an exploratory phase II program, it became our reference for all breast cancer patients who exhibited the indicators formally requiring anthracycline-based chemotherapy, such as metastatic disease at presentation [11] , locally advanced and inflammatory breast cancer [12] , and relapsing metastatic non-anthracycline-refractory patients. We present here the final results of this program in 86 consecutively treated relapsing breast cancer patients actually diagnosed and treated for locoregional disease.
Patients and methods

Eligibility
Only patients who had received adequate treatment for locoregional confined breast cancer (stage I-II) and had relapsed were entered in the study. No prior therapy for metastatic disease, either cytostatic or hormonal, was allowed. Patients who had completed an anthracyclinebased adjuvant chemotherapy less than 12 months before onset of metastasis were considered anthracycline-resistant and were excluded. To be eligible, patients had to fulfill the following criteria: age under 70, performance status 0-1, adequate blood count, adequate liver and renal functions, at least one evaluable and/or measurable lesion. Cardiac function was assessed before accrual by gated radionuclide ejection fraction and had to be greater than 55%. Thorough evaluation of metastatic extent included physical examination, mammograms, X-ray and/or CT-scan of the chest, isotopic bone scan and X-ray of detected lesions, abdominal ultrasonography and/or CT-scan. CEA and CA 15-3 serum tumor markers were also obtained. Central nervous system (CNS) metastases were not an exclusion criterion. All of the patients gave their informed consent.
Treatment
The chemotherapy regimen delivered epirubicin 75 mg/m 2 and cyclophosphamide 1200 mg/m 2 every 14 days for 6 consecutive courses. Patients were hospitalized in the afternoon and released during the morning of the following day. Chemotherapy was delivered with 4 liters of isotonic saline serum, and systematic anti-emetic medication with neuroleptic drugs or serotonin antagonists (after 1990) as well as corticosteroids. Complete blood count was measured twice a week, and daily in instances of neutropenic fever. Red blood cells and platelets were to be transfused when hemoglobin was under 8 g/dl and platelets under 20 x 10 9 /l, or if clinically indicated. Hematopoietic growth factors and stem-cell support were not prophylactically used after they had been made available, but were allowed in instances of persistent febrile neutropenia. Oral broad-spectrum prophylactic antibiotherapy was given after each course during the period of neutropenia, with trimethoprime-sulfametoxazole (400-800 mg twice daily) from 1985 to 1990, and with cefixime (200 mg twice daily) from 1990 to 1995. All patients with persistent febrile neutropenia (longer than 48 hours) or in whom it was suspected were rehospitalized for evaluation and intravenous synergistic bactericidal antibiotherapy. The chemotherapy was resumed after 48 hours of apyrexia, whatever the neutrophil count. Dose reductions and treatment delays were not allowed, and the treatment was repeated on the fourteenth day whatever the neutrophil count, unless the patient presented febrile neutropenia. Since dose reductions were not employed, the calculation of the doseintensity (DI) was simplified to the following formula: DI = [Date Cn -Date Cl]/[14 x (n-1)], where n represents the total number of courses which were actually delivered to a given patient, the difference between 'Date Cn'and'Date Cl' being expressed in days, with Mas the theoretical interval between two courses.
The efficacy of the regimen was evaluated only once, one month after completion of the six courses (on approximately day 100 after the first course), and included evaluation and/or measurement of all targets. Responses were coded according to WHO criteria [13] . Bone response in patients with bone metastases were coded according to the following site-specific modified criteria [14] . Complete response: complete disappearance of bone pain, hypercalcemia, and all isotopic or X-ray abnormalities; partial response: improvement of iconographic evidence and disappearance of clinical and biochemical signs: stable disease: improvement of symptoms; progressive disease: appearance of new bone lesions, and/or any complication due to bone metastases. Patients who achieved an objective response or who had stable disease were given maintenance chemotherapy consisting of a six-month outpatient alternation regimen including cyclophosphamide/methotrexate 5-fluorouracil (CMF) (months one and four), a combination of 5-fluorouracil, methotrexate and vincristine (months two and five), and 5-fluorouracil/adriamycin/cyclophosphamide (FAC, months three and six). Tamoxifen was added for patients whose primary tumor expressed estrogen receptors (ER), provided they had not received and/or had failed adjuvant hormonal therapy. A few (seven) patients with objective responses were also included in a late intensification program with autologous bone marrow transplantation including mitoxantrone, melphalan and cyclophosphamide [15] . Patients with progressive disease during or after completion of the study regimen were given vinorelbine-or, more recently, docetaxel-based regimens. Patients with CNS disease were not given radiation therapy unless they showed evidence of progressive and/or symptomatic disease.
Statistical analysis
Descriptive statistics are reported as percentages, medians or means. When necessary, they were compared with Fisher's exact test, or with an analysis of variance after Levene's test for homogeneity [16] . All patients were included in the analysis. Overall survival and PFS were defined from the date of the first course to the date of death or disease progression. Progressive disease was defined according to WHO criteria, including contralateral breast cancer. Survival curves were constructed using the Kaplan and Meier product-limit method [17] . Univariate analysis of prognostic factors for OS and PFS was conducted by the log-rank test [18] using the following variables: age (<40 vs. >40), ER (+ vs. -), Scarff-Bloom and Richardson (SBR) grade (1-2 vs. 3), pN (0 vs. 1-4 vs. 5+), adjuvant chemotherapy (yes vs. no), disease-free interval (DFI, <2 vs. >2 years), visceral metastasis (yes vs. no), number of sites involved (1 vs. > 1). Multivariate analysis was then performed in a stepwise manner using Cox's proportional hazards regression model [18] , including all variables with P < 0.05. All tests were two-sided.
Results
Patients
Eighty-six patients were entered in the study between May 1986 and June 1995, and data were acquired up until July 1998. Accrual proceeded cautiously at the beginning af the study (two patients included in 1986), and became regular after 1990, as the toxicity appeared to be manageable. Between 10 and 15 patients per year were included from 1990, which accounts for 10% of all metastatic patients referred to our center during the same period of time. Other patients were either non-eligible, or included in other studies. The same protocol was proposed to patients with non-metastatic locally advanced breast cancer, but these patients are analyzed in a separate study (manuscript under preparation). Eightyfour patients (98%) had stage I II disease at diagnosis, and the characteristics of the population are shown in Table 1 . Pathology at diagnosis was infiltrating ductal carcinoma in 73% of cases, and 56% of the tumors were hormone receptor (ER and/or PR)-positive (i.e., ^ 10 fmol/mg of protein). Initial therapy consisted of surgery, followed by radiation therapy in node-positive patients or those who had undergone conservative surgery. Fortyeight patients (56%) had received adjuvant chemotherapy, half of them with anthracyclines. The median diseasefree interval between breast cancer diagnosis and metastatic relapse was 31 months (5-122). Forty-six patients (53%) had at least one visceral metastatic site, including (11) 49 (57) 37 (43) 67 (79) 40 (64) 23 (37) 28 (56) 22 (44) 28 (56) 22 (44) 22 (24) 26 (31) 38 (44) 46 (55) 27 (33) 25 (30) 24 (29) 12 (14) 8 (14) 11 ( twenty-five with liver metastases. The same proportion (53%) had two or more involved metastatic sites.
Toxicity
Toxicity data are summarized in Table 2 , and were evaluated in 509 courses. There were no toxic deaths. When all of the courses were taken into account, grade 3-4 neutropenia was observed in most (80%) of the patients treated. Grade 4 neutropenia was more common with further courses: 40% of patients at course 1, and 71% at course 6 ( Figure 1 ). Grade 4 neutropenia was of short duration (median: three days), and resulted in neutropenic fever in 5% to 18% of courses, requiring rehospitalization in 5% to 10% of courses. These rates did not increase through successive treatment courses ( Figure 1 ). Severe red blood cell and platelet toxicity was moderate. Blood transfusion was required in 6% to 19% of patients (Table 2) , and only seven patients experienced grade 3-4 thrombocytopenia. Hematological recovery was complete after the last course of induction chemotherapy. Grade 3-4 emesis was experienced by 15% to 24% of the patients (Table 2) . We did not observe any cystitis or clinically significant mucositis. No clinical cardiac toxicity was observed, during or after the treatment, as assessed by clinical examination, and by gated radionuclide scan at the end of the program. The treatment was feasible as planned. Treatment compliance was excellent, as 85 patients (99%) received more than 80% of planned treatment, with four patients having five courses instead of six because of repeated febrile neutropenia. The single patient discontinuing treatment earlier (three courses) had progressive disease. Thus, 81 patients (94%) received the treatment as planned. Further evidence is given by a median DI of 97% (79-106), and 97% of the patients had a DI equal to, or greater than 90%. The maintenance or second-line chemotherapy was administered without any prohibitive or unusual toxicity (data not shown).
Response
Two patients were not evaluable for response (one patient lost to follow-up and one patient with missing data). Sixteen patients (19%) with exclusively bone metastasis were considered as having stable disease at the end of induction therapy, since it was too early to have evidence of bone recalcification. The objective response rate (ORR) for the 84 evaluable patients is shown in Table 3 . ORR was 54% (95% confidence interval (95% CI): 43-65), including an 11% complete response rate (95% CI: 4-18). Patients with lymph node, lung, pleural, or skin metastasis responded best, with response rates of 70%, 50%, 45% and 45%, respectively. The response rate in 11 patients with CNS metastases was 45%. Partial response was achieved in four patients with carcinomatous meningitis (persistent or isolated hyperproteinorachia) and in one patient with epidural metastasis, and stable disease was observed in two patients with brain metastasis and in one patient with epidural metastasis. Progressive disease was observed in 14% of the patients, during (only one patient) or after the treatment. At the end of planned treatment, nonprogressing patients received tamoxifen (four patients), while seven patients received late high-dose chemotherapy [15] . The remaining 61 patients received the maintenance therapy program.
Survival
As of July 1998, with a median follow-up period of 42 months (6-122), 77 patients have died, and all but 5 have progressed. Progression-free (PFS) and overall (OS) survivals are shown in Figure 2 . A median PFS of 16 months has been achieved, with a median OS of 32 months. Actuarial two-year OS was 62% (95% CI: 56-68) and 39% at three years (95% CI: 33-46). Seven patients received high-dose chemotherapy; eliminating them from the survival analysis did not alter the results (data not shown). Thirteen long-term (>4 years) surviving patients had lung or extra-visceral metastasis, and responded at least partially to induction chemotherapy. One of them received late high-dose chemotherapy, and the remaining 12 received conventional maintenance chemotherapy (8 with lung and 4 with extra-visceral metastasis). Univariate analysis of patient and disease characteristics for their prognostic value for survival was performed with the log-rank test, and significant results are shown in Table 4 . Age and tumor characteristics such as hormonal receptors, histoprognostic grade, number of involved axillary lymph nodes were not correlated to prognosis. The absence of adjuvant chemotherapy, a single metastatic site, and the absence of visceral metastasis were associated with both a longer OS and a longer PFS. A prolonged DFI between primary diagnosis and onset of metastatic disease was also associated with prolonged OS, but not with PFS. In multivariate analysis, adjuvant chemotherapy and DFI for OS, adjuvant chemotherapy for PFS, were the only predictors of survival. Associated relative risks and statistical significance are given in Table 4 . Patients who had previously received adjuvant chemotherapy were more likely to have involved axillary lymph nodes at diagnosis (P < 0.00001, Fisher's exact test), but otherwise had the same characteristics as the other patients. The proportion of patients with visceral metastases was 56% for patients who had received adjuvant chemotherapy and 54%, for those who had not. Overall survival according to adjuvant chemotherapy status is shown in Figure 3 .
Discussion
We present here the results of an accelerated chemotherapy regimen used as a first-line treatment for metastatic breast cancer patients. When this treatment was Survival Time (months) Figure 3 . Overall survival according to adjuvant chemotherapy status.
initiated in 1986, it was considered aggressive by therapeutic standards of the time, since there were no published results and very little experience of such chemotherapy with shortened intervals [10, 19] . Furthermore, hematopoietic growth factors did not become available until 1990. The first issue we addressed was the feasibility of such a protocol in an outpatient setting. The program needed close and frequent follow-ups, requiring only 12-15 days of hospitalization for all of the patients over a three-month period. More than 90% of patients received the chemotherapy at the planned doses and on the planned day. Grade 3-4 leukoneutropenia was frequent but of short duration, and induced few clinical consequences. The role of oral prophylactic antibiotherapy is quite difficult to specify, but has probably resulted in a limitation of the clinical consequences of repeated grade 4 neutropenia [20] . As the observed proportion of patients experiencing febrile neutropenia was less than 20%, we did not consider the preventive use of G-CSF or GM-CSF necessary after 1990. An approximate cost comparison can be made between G-CSF and prophylactic antibiotics on the following basis: cefixime per eight days for six courses: 1106.40 french francs; filgrastim for eight days for six courses: 12.000 french francs (1995 prices). This underlies the potential cost-effectiveness of prophylactic antibiotics compared to a systematic preventive use of G-CSF. The excellent cardiotoxicity profile of epirubicin below a cumulative dose of 1000 mg/m 2 is also confirmed, even in patients with a record of previous anthracyclinebased adjuvant chemotherapy.
The novel presentation here of only relapsing patients makes our study relevant to the current population of advanced breast cancer patients, with most patients having received adequate treatment for their early breast cancer. Young age and a long DFI were the main basal characteristics of our cohort, although 54% of patients had visceral metastases, 25 of them (30%) with liver disease, and 11 (13%) with CNS disease. The outcome results (only a secondary endpoint) we report here in terms of response rate and time-related parameters have therefore to be cautiously interpreted. The response rate we have reported (54%, with an 11 % complete response rate) does not appear higher than usual, probably because the frequency of observations did not allow us to adequately evaluate metastatic bone disease [21] . A second explanation might be the high proportion of patients (56%) who had received adjuvant chemotherapy. These patients had a response rate of 41%, which was significantly different from the 69% response rate observed in the subset of patients who had not received adjuvant chemotherapy (P = 0.02, Fisher's exact test). Prior adjuvant chemotherapy is acknowledged as being an adverse prognostic factor in metastatic breast cancer [3, [22] [23] [24] . We observed a median PFS of 16 months and a median OS of 32 months. Analysis of prognostic factors for survival showed that adjuvant chemotherapy, and the DFI between initial diagnosis and onset of metastasis were the strongest independent predictors of prolonged survival. In one multivariate analysis including 326 patients, Venturini et al. found that prior adjuvant chemotherapy, with or without anthracyclines, was the best predictor of PFS and OS for metastatic breast cancer patients [24] . In our study, prior adjuvant chemotherapy was associated with a lower survival time (median PFS 10 vs. 22 months, P -0.02), whatever the combination, i.e., with or without anthracyclines (P -0.76 and 0.78, for PFS and OS, respectively). Unlike other studies, visceral involvement was not associated with poor prognosis in multivariate analysis [3, 25] . The effect of maintenance chemotherapy on survival cannot be assessed in this non-randomized study, but several studies suggest a significantly longer PFS with maintenance chemotherapy [22, 26] .
The high-dose density anthracycline-based treatment of advanced breast cancer has been previously reported, particularly studies in the dose-intensification of an epirubicin-cyclophosphamide combination [27] [28] [29] . It appears from the data of Piccart [29] and Lalisang [28] that an average weekly dose intensity of 40-60 mg/m 2 of epirubicin and 200-400 mg/m 2 of cyclophosphamide is feasible. We achieved a weekly dose intensity of 37.5 mg/m 2 of epirubicin and 600 mg/m 2 of cyclophosphamide. The incidence of febrile neutropenia does not appear to be any higher in our study. Furthermore, we observed grade 3-4 thrombocytopenia in only 8% of the patients. Again, we did not use any hematopoietic growth factor. Few efficacy data are available from these relatively small series. Nevertheless, the time-related parameter results of our present study seem to be very encouraging when compared to both the results from the latter studies and to those obtained with high-dose consolidation chemotherapy followed by autologous bone marrow support. Gisselbrecht et al. reported the results of their study on 61 women with metastatic breast cancer who responded to conventional induction chemotherapy, and who received high-dose chemotherapy with G-CSF and autologous bone marrow transplantation [15] . Median event-free survival was 13 months, and median OS was 33 months. Antman et al. reported the data from the Autologous and Bone Marrow Transplant Registry of North America, concerning 3451 women with metastatic breast cancer [30] . The profile of that population was similar to that of the population in the present study: median age 44 years, visceral metastases 49%. Sensitivity to pretransplant conventional chemotherapy was assessed in 80% of the patients, and 63% exhibited complete or partial response. However, median survival was only 19 months, and median PFS was about 6 months.
Our pilot study, started over 12 years ago, is presented here as a set of fully analyzed mature data. Dose-dense treatment without dose reduction and with dose delays allowing only for severe morbidity was feasible. We achieved our treatment objectives with encouraging timerelated parameter results. Issues raised by the present report include the study of the role of sequential highdose chemotherapy regimens followed by stem-cell support as first-line treatment, and the inclusion in such approaches of new drugs such as vinorelbine, docetaxel or paclitaxel, because of their demonstrated activity in this setting, either alone or in association [31, 32] . Confirmatory randomized trials are nevertheless eagerly awaited, even if preliminary results in high-risk or locally advanced breast cancer are disappointing [33] , and their future design will depend on the results of these preliminary studies.
